Salamanca Press

Results of part 1 of the ESSENCE phase 3 trial, published in The New England Journal of Medicine , demonstrated that a greater proportion of patients ...

All doses of FDA-approved Wegovy ® , the most widely prescribed and studied GLP-1 for weight loss, are now accessible to patients of select telehealth...

PLAINSBORO, N.J. , April 14, 2025 /PRNewswire/ -- Novo Nordisk has become aware of several hundred units of Ozempic ® (semaglutide) injection 1 mgdist...

PLAINSBORO, N.J. , March 29, 2025 /PRNewswire/ -- Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial investigat...

PLAINSBORO, N.J. , March 29, 2025 /PRNewswire/ -- NovoNordisk today presented results from STRIDE, its phase 3b trial investigating the effects of onc...

PLAINSBORO, N.J. , March 17, 2025 /PRNewswire/ -- Novo Nordisk today announced new data for semaglutide medicines to be presented at the American Coll...

PLAINSBORO, N.J. , March 5, 2025 /PRNewswire/ -- As part of its ongoing efforts to ensure patients who need Wegovy ® (semaglutide) injection 0.25 mg, ...

PLAINSBORO, N.J. , March 3, 2025 /PRNewswire/ -- Novo Nordisk launched "My Ozempic ® Era" today, a national campaign which spotlights the longstanding...

PLAINSBORO, N.J. , Feb. 21, 2025 /PRNewswire/ -- Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has determined the shortage o...